title: Effect of non-persistent use of oral glucose-lowering drugs on HbA1c goal attainment.
abstract: OBJECTIVE
  The aim of this study was to quantify the effect of non-persistence with oral glucose-lowering drugs (OGLD) on HbA(1c) goal attainment (<7%) in daily practice.
  
  
  METHODS
  From the PHARMO Record Linkage System comprising among others linked drug dispensing and clinical laboratory data from approximately 2.5 million individuals in the Netherlands, new users of OGLD in the period 1999-2004 were identified. Patients with a baseline HbA(1c) > or =7% and at least one HbA(1c) measurement in the period of 6-12 months after treatment onset were included in the study cohort. Persistence with OGLD in the first year of treatment was determined using the method of Catalan. In case the first treatment episode overlapped the first HbA(1c) measurement within 6-12 months after treatment onset, a patient was considered persistent at that measurement. Patients with a HbA(1c) <7% were defined as having attained goal.
  
  
  RESULTS
  The study cohort included 2023 patients with a mean baseline HbA(1c) of 8.9 +/- 1.8%. Three-quarters (1512 patients) were persistent with any OGLD at the first HbA(1c) measurement within 6-12 months after treatment onset; of these, 861 (57%) were at goal. Of the 511 non-persistent patients, 239 (47%) were at goal. Non-persistent patients were about 20% less likely to attain goal (RRadj 0.82; 95%CI 0.74-0.91), compared to persistent OGLD users.
  
  
  CONCLUSIONS
  Non-persistent use of OGLD leads to a 20% decreased probability of HbA(1c) goal attainment in daily practice. This effect of non-persistence seems modest, but represents around 12 000 new and 10 000 prevalent OGLD users a year in the Netherlands in whom OGLD use could be better controlled.
authors.affiliation: PHARMO Institute, Utrecht, The Netherlands. fernie.penning@pharmo.nl
authors.forename: Fernie J A
authors.initials: FJ
authors.lastname: Penning-van Beest
authors.forename: Sjoukje
authors.initials: S
authors.lastname: van der Bij
authors.forename: Joëlle A
authors.initials: JA
authors.lastname: Erkens
authors.forename: Sophia
authors.initials: S
authors.lastname: Kessabi
authors.forename: Martijn
authors.initials: M
authors.lastname: Groot
authors.forename: Ron M C
authors.initials: RM
authors.lastname: Herings
mesh_terms: D000284:Administration, Oral; D000328:Adult; D000368:Aged; D015331:Cohort Studies; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000188:drug therapy*; D005260:Female; D006442:Glycated Hemoglobin / Q000032:analysis*; D006801:Humans; D007004:Hypoglycemic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D016896:Treatment Outcome
chemical_list: D006442:Glycated Hemoglobin; D007004:Hypoglycemic Agents